Anthony Atala to Urinary Bladder Neoplasms
This is a "connection" page, showing publications Anthony Atala has written about Urinary Bladder Neoplasms.
Connection Strength
15.158
-
Atala A. Re: A Genetically Defined Disease Model Reveals That Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes. J Urol. 2020 12; 204(6):1384-1385.
Score: 0.597
-
Atala A. Re: The CUL4B-miR-372/373-PIK3CA-AKT Axis Regulates Metastasis in Bladder Cancer. J Urol. 2020 10; 204(4):882.
Score: 0.591
-
Atala A. Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer Progression. J Urol. 2020 09; 204(3):622-623.
Score: 0.586
-
Atala A. Re: A Genetically Defined Disease Model Reveals that Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes. J Urol. 2020 08; 204(2):389.
Score: 0.582
-
Atala A. Re: Hypermethylation of FOXA1 and Allelic Loss of PTEN Drive Squamous Differentiation and Promote Heterogeneity in Bladder Cancer. J Urol. 2020 07; 204(1):188.
Score: 0.578
-
Atala A. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression. J Urol. 2020 05; 203(5):885.
Score: 0.572
-
Atala A. Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs. J Urol. 2020 05; 203(5):884-885.
Score: 0.572
-
Atala A. Re: Epigenetic Loss of AOX1 Expression via EZH2 Leads to Metabolic Deregulations and Promotes Bladder Cancer Progression. J Urol. 2020 04; 203(4):666.
Score: 0.569
-
Atala A. Re: Recurrent Activating Mutations of PPAR? Associated with Luminal Bladder Tumors. J Urol. 2019 11; 202(5):869.
Score: 0.559
-
Atala A. Re: Bladder Cancer Extracellular Vesicles Drive Tumorigenesis by Inducing the Unfolded Protein Response in Endoplasmic Reticulum of Nonmalignant Cells. J Urol. 2019 12; 202(6):1100-1101.
Score: 0.556
-
Atala A. Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research. J Urol. 2019 10; 202(4):664.
Score: 0.555
-
Atala A. Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment. J Urol. 2019 04; 201(4):669.
Score: 0.539
-
Vasyutin I, Zerihun L, Ivan C, Atala A. Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling. Anticancer Res. 2019 Mar; 39(3):1105-1118.
Score: 0.536
-
Atala A. Re: Identification of MicroR-106b as a Prognostic Biomarker of p53-Like Bladder Cancers by ActMiR. J Urol. 2019 02; 201(2):231.
Score: 0.533
-
Atala A. Re: An FGFR3/MYC Positive Feedback Loop Provides New Opportunities for Targeted Therapies in Bladder Cancers. J Urol. 2018 11; 200(5):947-948.
Score: 0.515
-
Atala A. Re: Evasion of Immunosurveillance by Genomic Alterations of PPAR?/RXRa in Bladder Cancer. J Urol. 2018 05; 199(5):1115-1116.
Score: 0.499
-
Atala A. Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer. J Urol. 2017 11; 198(5):983-985.
Score: 0.481
-
Atala A. Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2. J Urol. 2017 11; 198(5):984-985.
Score: 0.481
-
Atala A. Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. J Urol. 2017 11; 198(5):985.
Score: 0.481
-
Atala A. Re: Claudin-Low Bladder Tumors are Immune Infiltrated and Actively Immune Suppressed. J Urol. 2017 05; 197(5):1220.
Score: 0.465
-
Atala A. Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness. J Urol. 2016 10; 196(4):1314.
Score: 0.447
-
Atala A. Re: Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer. J Urol. 2016 04; 195(4 Pt 1):1168-9.
Score: 0.432
-
Atala A. Re: Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival following Radiotherapy in Muscle-Invasive Bladder Cancer. J Urol. 2015 Oct; 194(4):1162-3.
Score: 0.416
-
Atala A. Re: TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer. J Urol. 2015 Sep; 194(3):848.
Score: 0.414
-
Atala A. Re: Mutations in 3'-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb. J Urol. 2015 Mar; 193(3):1061.
Score: 0.400
-
Atala A. Re: Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles Bladder Cancer Study. J Urol. 2014 Aug; 192(2):614-5.
Score: 0.384
-
Atala A. Re: Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. J Urol. 2013 Dec; 190(6):2306.
Score: 0.366
-
Atala A. Re: Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. J Urol. 2013 Oct; 190(4):1437.
Score: 0.362
-
Atala A. Re: PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. J Urol. 2013 Sep; 190(3):1131.
Score: 0.360
-
Atala A. Re: NMR-based metabolomics study of canine bladder cancer. J Urol. 2013 Aug; 190(2):808.
Score: 0.358
-
Atala A. Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo. J Urol. 2017 08; 198(2):258-259.
Score: 0.118
-
Atala A. Re: Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs and circRNAs with Associated Co-Expression and ceRNA Networks in Bladder Carcinoma. J Urol. 2017 01; 197(1):51-52.
Score: 0.113
-
Atala A. What's new in urology. J Am Coll Surg. 2004 Sep; 199(3):446-61.
Score: 0.049
-
Doherty SC, McKeown SR, McKelvey-Martin V, Downes CS, Atala A, Yoo JJ, Simpson DA, Kaufmann WK. Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst. 2003 Dec 17; 95(24):1859-68.
Score: 0.047
-
Godbey WT, Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther. 2003 Aug; 10(17):1519-27.
Score: 0.045